文档介绍：Articles
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for
fi rst-line treatment of patients with metastatic colorectal
cancer: a randomised, non-inferiority phase 3 trial
Yong Sang Hong, Young Suk Park, Ho Yeong Lim, Jeeyun Lee, Tae Won Kim, Kyu-pyo Kim, Sun Young Kim, Ji Yeon Baek, Jee Hyun Kim,
Keun-Wook Lee, Ik-Joo Chung, Sang-Hee Cho, Kyung Hee Lee, Sang Joon Shin, Hye Jin Kang, Dong Bok Shin, Sook Jung Jo, Jae Won Lee
Summary
Background Capecitabine plus oxaliplatin (CapeOX) is one of the reference doublet cytotoxic chemotherapy treatments Lancet Oncol 2012; 13: 1125–32
for patients with metastatic colorectal cancer. We aimed pare the effi cacy and safety of CapeOX with that of S-1 Published Online
plus oxaliplatin (SOX), a promising alternative treatment for patients with metastatic colorectal cancer. October 10, 2012
http://dx.//
S1470-2045(12)70363-7
Methods In this open-label, multicentre, randomised phase 3 trial, we randomly assigned patients (1:1) from
ment page 1068
11 institutions in South Korea to receive either CapeOX (capecitabine 1000 mg/m² twice daily on days 1–14 and
Department of Oncology, Asan
oxaliplatin 130 mg/m² on day 1) or SOX (S-1 40 mg/m² twice daily on days 1–14 and oxaliplatin 130 mg/m² on day 1). Medical Centre, University of
Treatment was repeated every 3 weeks and continued for as many as nine cycles